Avadel Pharmaceuticals plc (AVDL)
NASDAQ: AVDL · IEX Real-Time Price · USD
17.81
-0.01 (-0.06%)
At close: Apr 26, 2024, 4:00 PM
18.04
+0.23 (1.29%)
After-hours: Apr 26, 2024, 7:15 PM EDT
Avadel Pharmaceuticals Revenue
In the year 2023, Avadel Pharmaceuticals had annual revenue of $27.96M. Revenue in the quarter ending December 31, 2023 was $19.45M.
Revenue (ttm)
$27.96M
Revenue Growth
n/a
P/S Ratio
57.69
Revenue / Employee
$181,578
Employees
154
Market Cap
1.61B USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 27.96M | - | - |
Dec 31, 2022 | 0 | - | - |
Dec 31, 2021 | 0 | - | - |
Dec 31, 2020 | 22.33M | -36.88M | -62.28% |
Dec 31, 2019 | 59.22M | -44.05M | -42.66% |
Dec 31, 2018 | 103.27M | -69.98M | -40.39% |
Dec 31, 2017 | 173.25M | 23.00M | 15.31% |
Dec 31, 2016 | 150.25M | -22.76M | -13.16% |
Dec 31, 2015 | 173.01M | 158.03M | 1,055.32% |
Dec 31, 2014 | 14.98M | 10.80M | 258.34% |
Dec 31, 2013 | 4.18M | -3.36M | -44.53% |
Dec 31, 2012 | 7.53M | -25.07M | -76.89% |
Dec 31, 2011 | 32.60M | -4.49M | -12.12% |
Dec 31, 2010 | 37.09M | -5.02M | -11.93% |
Dec 31, 2009 | 42.12M | 3.50M | 9.06% |
Dec 31, 2008 | 38.62M | 1.97M | 5.36% |
Dec 31, 2007 | 36.65M | 13.63M | 59.23% |
Dec 31, 2006 | 23.02M | -578.00K | -2.45% |
Dec 31, 2005 | 23.60M | -31.81M | -57.41% |
Dec 31, 2004 | 55.41M | 30.24M | 120.17% |
Dec 31, 2003 | 25.17M | 6.76M | 36.73% |
Dec 31, 2002 | 18.41M | 5.32M | 40.64% |
Dec 31, 2001 | 13.09M | 2.19M | 20.04% |
Dec 31, 2000 | 10.90M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Addus HomeCare | 1.06B |
Myriad Genetics | 753.20M |
Warby Parker | 669.77M |
Taro Pharmaceutical Industries | 610.83M |
Supernus Pharmaceuticals | 607.52M |
U.S. Physical Therapy | 604.80M |
Harmony Biosciences Holdings | 582.02M |
UFP Technologies | 400.07M |
AVDL News
- 25 days ago - Avadel Pharmaceuticals to Present at the 23rd Annual Needham Healthcare Conference - GlobeNewsWire
- 7 weeks ago - Avadel Pharmaceuticals to Present at Upcoming Investor Conferences - GlobeNewsWire
- 7 weeks ago - Avadel Pharmaceuticals Issues Statement On Patent Litigation - GlobeNewsWire
- 7 weeks ago - Avadel Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results - GlobeNewsWire
- 6 months ago - Avadel Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2023 Financial Results - GlobeNewsWire
- 6 months ago - Avadel Pharmaceuticals Announces Data Supporting Clinical Profile for LUMRYZ™ (sodium oxybate) for extended-release oral suspension (CIII) at World Sleep 2023 - GlobeNewsWire
- 7 months ago - Avadel Pharmaceuticals to Present at the Jefferies Biotech CNS/Neuro Summit - GlobeNewsWire
- 9 months ago - Avadel Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2023 Financial Results - GlobeNewsWire